BeyondSpring's lung cancer combo gets FDA fast-track status as cash drops to $0.6m

BeyondSpring paired a regulatory boost with a stark balance sheet in its third-quarter update on 13 November 2026. The US Food and Drug Administration has given fast-track status to plinabulin combined with docetaxel, while the company reported cash of $0.6 million and a quarterly net loss of $2.1 million.

The designation applies to patients with advanced or metastatic non-squamous non-small cell lung cancer who have no actionable genomic alterations and whose disease has worsened after a PD-1 or PD-L1 checkpoint inhibitor and platinum-based chemotherapy. BeyondSpring says this is the same group enrolled in its Phase 3 DUBLIN-4 trial. As context, fast track is meant to speed development of drugs for serious conditions with unmet need. It permits more frequent contact with the agency and, if criteria are met, rolling submission of an application. It does not lower the evidence bar for approval.

The company also said it closed the sale of its subsidiary holding the Bulin business to Biolin on 30 September. Under the update, Biolin will fund about half of the 442 patients to be enrolled in DUBLIN-4 in China, which bears on both the cost of running the study and the geographic mix of its data.

The material available did not set out trial timelines or explain how the rest of the enrolment will be paid for, leaving open how the company will bridge from its current cash level to a readout.